Eli Lilly – The Milli Chronicle

Saturday, November 8, 2025

Latest:

Wall Street Market Adjustments Reflect Broader Economic Considerations
Gates Foundation Commits $1.4 Billion to Support Climate-Resilient Farming
U.S. Emphasizes Energy Security Through Balanced Approach to Oil, Gas, and Renewables
US Government Launches Generous Model to Cut Medicaid Prescription Costs
Wall Street Applauds Tesla Shareholders’ Landmark Approval of Elon Musk’s $1 Trillion Performance-Based Pay Package

Factual Version of a Story

NewsDesk Milli Chronicle November 7, 2025 active pharmaceutical ingredients, API demand, API exports, API manufacturing, API production growth., biotechnology India, CDMO services, contract manufacturing, diabetes drugs, Divi’s Laboratories, Divi’s profits, drug manufacturing, Eli Lilly, European pharma, global healthcare, global pharma supply chain, Hyderabad pharma company, India drugmakers, Indian pharmaceutical exports, Novo Nordisk, pharma growth India, pharma industry trends, pharma investment, pharmaceutical innovation, pharmaceutical R&D, sustainable manufacturing, US market pharma, weight-loss drugs

Divi’s Laboratories Reports Strong Q2 Growth, Driven by Rising API Demand and Global Expansion

Hyderabad – Indian pharmaceutical giant Divi’s Laboratories outperforms expectations with a surge in profits and strong export performance amid growing

Asia Latest News

NewsDesk Milli Chronicle November 7, 2025November 7, 2025 Cipla, diabetes care India, diabetes control, diabetes treatment India, Eli Lilly, Eli Lilly India, GLP-1 drugs, healthcare growth India, healthcare technology, Hyderabad health innovation, India pharma market, medical innovation, metabolic health, Mounjaro, Novo Nordisk, obesity awareness, obesity treatment, pharmaceutical sales India, Wegovy, weight management therapy, weight-loss drug India, weight-loss injection

Eli Lilly’s Mounjaro Becomes India’s Top-Selling Drug, Signaling a New Era in Healthcare Innovation

Hyderabad – Eli Lilly’s groundbreaking weight-loss and diabetes treatment, Mounjaro, takes the top spot in India’s pharmaceutical market, marking a

U.S. Strikes Breakthrough Deal to Boost Access to Weight-Loss Drugs

A landmark public-private partnership aims to make life-changing obesity and diabetes treatments more affordable and accessible for millions across America.

Novo Nordisk Nears Completion of Global Restructuring, Poised for Stronger Growth Ahead

Novo Nordisk’s global transformation plan, including the restructuring of its workforce, is nearly complete, signaling the company’s focus on innovation,

Asia Health Latest Lifestyle News

NewsDesk Milli Chronicle September 25, 2025September 25, 2025 anti-obesity medication, clinical trials, diabetes and obesity treatment, diabetes medication, Eli Lilly, Eli Lilly India launch, Eli Lilly pharmaceutical update, experimental obesity drug, GLP-1 receptor agonist, GLP-1 treatment, health innovation, healthcare news India, innovative healthcare solutions, medical breakthrough India, new drug approval India, obesity management, pharmaceutical industry India, pharmaceutical launch India, weight management therapy, weight-loss pill India

Eli Lilly plans to bring experimental weight-loss pill in India

Mumbai, (Reuters) – Eli Lilly (LLY.N),plans to launch its experimental oral weight-loss drug orforglipron in India, a senior executive said on